Osimertinib retreatment for patients with advanced EGFR-mutated non-small cell lung cancer
{{output}}
Resistance to osimertinib, a third-generation EGFR tyrosine kinase inhibitor, remains a key challenge in the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). Although retreatment with earlier-generation EGFR tyrosine kinase inhibitors has been stu... ...
